NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$24.16
+0.16 (+0.67%)
Close of Nov 06, 2026 · end-of-day data
VCYT 8-K filings in 2024
Every material Form 8-K Veracyte filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Veracyte reported third-quarter 2024 total revenue of $115.9 million, up 29% from a year earlier, and net income of $15.2 million, compared with a net loss of $29.6 million in the third quarter of 2023. The company raised its full-year 2024 total revenue guidance to $442 million to $445 million, from $432 million to $438 million previously.
Total revenue of $115.9 million, up 29% from $90.1 million; testing revenue of $109.5 million, up 34%
Diluted EPS of $0.19 (GAAP), compared with a loss of $0.41 per share a year earlier; non-GAAP diluted EPS of $0.33
Full-year 2024 total revenue guidance raised to $442 million to $445 million; year-end cash guidance raised to $280 million to $285 million
Third-quarter cash from operations of $30.0 million; cash and cash equivalents of $274.1 million at September 30, 2024
Veracyte's board appointed Tom Miller, Ph.D., and Brent Shafer as directors on September 3, 2024, effective immediately, following a recommendation from the Nominating and Corporate Governance Committee. The filing describes routine board additions with standard director compensation and indemnification terms, and does not disclose any financial results or changes to company operations.
Board appointed Tom Miller, Ph.D., and Brent Shafer as directors on September 3, 2024, effective immediately.
Dr. Miller joins the Regulatory and Compliance Committee; Mr. Shafer joins the Compensation Committee.
Both directors are eligible for the non-employee director compensation program and signed the company's standard indemnity agreement.
Their terms run until the 2025 annual meeting of stockholders or until a successor is elected.
Veracyte reported second-quarter 2024 total revenue of $114.4 million, up 27% from $90.3 million a year earlier, and swung to net income of $5.7 million from a net loss of $8.4 million. The company raised its full-year 2024 total revenue guidance to $432 million to $438 million from $402 million to $410 million, which is a positive signal for shareholders.
Q2 2024 total revenue was $114.4 million, up 27% from $90.3 million in Q2 2023; testing revenue rose 31% to $107.0 million.
Net income was $5.7 million, or $0.07 per diluted share, versus a net loss of $8.4 million, or $(0.12) per share, in Q2 2023.
Adjusted EBITDA was $24.0 million, or 21% of revenue, compared with $11.0 million, or 12% of revenue, a year earlier.
Full-year 2024 total revenue guidance rose to $432 million to $438 million; year-end cash guidance rose to $260 million to $270 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Veracyte filing is on SEC EDGAR ↗. 8-K briefs of other companies →